News
PRTA
51.00
+0.04%
0.02
Prothena: Correspondence
Press release · 2d ago
Prothena: [Cover]SEC-generated letter
Press release · 2d ago
Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise
Seeking Alpha · 2d ago
Weekly Report: what happened at PRTA last week (0911-0915)?
Weekly Report · 5d ago
Alzheimer's drug developers get lift from Anavex results
Seeking Alpha · 09/14 17:02
Weekly Report: what happened at PRTA last week (0904-0908)?
Weekly Report · 09/11 09:17
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why
NASDAQ · 09/07 16:00
Researchers study weight loss drugs in dementia and addiction
Seeking Alpha · 09/07 15:04
Weekly Report: what happened at PRTA last week (0828-0901)?
Weekly Report · 09/04 11:17
Prothena: Statement of changes in beneficial ownership of securities
Press release · 08/31 00:04
Prothena: Report of proposed sale of securities
Press release · 08/30 21:21
More
Webull provides a variety of real-time PRTA stock news. You can receive the latest news about Prothena through multiple platforms. This information may help you make smarter investment decisions.
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.